Atala Financial Inc Invests $53,000 in Stryker Co. (NYSE:SYK)

Atala Financial Inc purchased a new stake in Stryker Co. (NYSE:SYK) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 147 shares of the medical technology company’s stock, valued at approximately $53,000.

A number of other hedge funds have also recently added to or reduced their stakes in the company. J. W. Coons Advisors LLC increased its stake in shares of Stryker by 0.7% during the 4th quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company’s stock worth $1,315,000 after purchasing an additional 26 shares during the last quarter. Mascoma Wealth Management LLC boosted its holdings in Stryker by 22.7% in the fourth quarter. Mascoma Wealth Management LLC now owns 146 shares of the medical technology company’s stock worth $53,000 after purchasing an additional 27 shares in the last quarter. Opal Wealth Advisors LLC increased its position in Stryker by 1.6% during the fourth quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company’s stock worth $654,000 after buying an additional 28 shares during the last quarter. Lindbrook Capital LLC raised its holdings in Stryker by 2.0% during the fourth quarter. Lindbrook Capital LLC now owns 1,407 shares of the medical technology company’s stock valued at $507,000 after buying an additional 28 shares in the last quarter. Finally, Alhambra Investment Management LLC lifted its position in shares of Stryker by 1.5% in the fourth quarter. Alhambra Investment Management LLC now owns 1,997 shares of the medical technology company’s stock worth $719,000 after buying an additional 29 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insiders Place Their Bets

In other news, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the transaction, the director now owns 14,895 shares in the company, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company’s stock.

Stryker Stock Up 1.7 %

SYK opened at $369.96 on Friday. The company has a market capitalization of $141.17 billion, a P/E ratio of 47.68, a P/E/G ratio of 2.93 and a beta of 0.95. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The firm’s fifty day moving average price is $383.04 and its two-hundred day moving average price is $373.37. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter last year, the company posted $3.46 EPS. On average, analysts anticipate that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.91%. The ex-dividend date is Monday, March 31st. Stryker’s dividend payout ratio (DPR) is 43.30%.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Needham & Company LLC reissued a “buy” rating and issued a $442.00 price objective on shares of Stryker in a research note on Wednesday, January 29th. Argus set a $450.00 price target on shares of Stryker in a research report on Monday, February 3rd. Morgan Stanley raised shares of Stryker from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $370.00 to $445.00 in a report on Monday, December 2nd. Citigroup reiterated a “buy” rating and issued a $450.00 target price on shares of Stryker in a report on Wednesday, February 26th. Finally, The Goldman Sachs Group set a $422.00 price target on shares of Stryker in a report on Tuesday, March 4th. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $421.90.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.